Abstract
PP01.53 Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have